Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. by Menon, Madhu P et al.
Primary CNS T-cell Lymphomas
A Clinical, Morphologic, Immunophenotypic,
and Molecular Analysis
Madhu P. Menon, MD, PhD,* Alina Nicolae, MD, PhD,* Hillary Meeker,* Mark Raﬀeld, MD,*
Liqiang Xi, MD,* Armin G. Jegalian, MD, PhD,* Douglas C. Miller, MD, PhD,w
Stefania Pittaluga, MD, PhD,* and Elaine S. Jaﬀe, MD*
Abstract: Primary central nervous system (CNS) lymphomas are
relatively rare with the most common subtype being diﬀuse large
B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL)
account for <5% of CNS lymphomas. We report the clinical,
morphologic, immunophenotypic, and molecular characteristics of
18 PCNSTLs. Fifteen cases were classiﬁed as peripheral T-cell
lymphoma, not otherwise speciﬁed, 2 of which were of gd T-cell
derivation and 1 was TCR silent; there was 1 anaplastic large cell
lymphoma, ALK-positive and 2 anaplastic large cell lymphoma,
ALK-negative. Median age was 58.5 years (range, 21 to 81y), with
an M:F ratio of 11:7. Imaging results showed that 15 patients had
supratentorial lesions. Regardless of subtype, necrosis and peri-
vascular cuﬃng of tumor cells were frequently observed (11/18
cases). CD3 was positive in all cases but 1; 10/17 were CD8-positive,
and 5/17 were CD4-positive. Most cases studied had a cytotoxic
phenotype with expression of TIA1 (13/15) and granzyme-B (9/13).
Polymerase chain reaction analysis of T-cell receptor g rearrange-
ment conﬁrmed a T-cell clone in 14 cases with adequate DNA
quality. Next-generation sequencing showed somatic mutations in
36% of cases studied; 2 had >1 mutation, and none showed
overlapping mutations. These included mutations in DNMT3A,
KRAS, JAK3, STAT3, STAT5B, GNB1, and TET2 genes, genes
implicated previously in other T-cell neoplasms. The outcome was
heterogenous; 2 patients are alive without disease, 4 are alive with
disease, and 6 died of disease. In conclusion, PCNSTLs are histo-
logically and genomically heterogenous with frequent phenotypic
aberrancy and a cytotoxic phenotype in most cases.
Key Words: T-cell lymphoma, central nervous system, next-
generation sequencing, gd T cells, T-cell clonality, molecular
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(Am J Surg Pathol 2015;39:1719–1729)
Primary central nervous system (CNS) lymphoma(PCNSL) is a relatively rare disease accounting for 2%
to 6% of all primary brain malignancies and 1% to 2% of
non-Hodgkin lymphoma.1–5 These lymphomas are deﬁned
as being conﬁned to the brain, spinal cord, or the eye
without extra-CNS or lymph node manifestations at pre-
sentation.1–6 However, late relapses outside the CNS can
occur.3,6 Although diﬀuse large B-cell lymphoma (DLBCL)
is the most common type of PCNSL (with primary DLBCL
of CNS enjoying a separate category in the current World
Health Organization classiﬁcation), other lymphomas in-
cluding Burkitt lymphoma, mucosa-associated lymphoid
tissue lymphomas (dura), follicular lymphoma, and T-cell
lymphomas can present with intracranial disease.2,3,7,8 The
reported percentage of PCNSL of T-cell derivation
TABLE 1. Antibodies Used in the Immunophenotypic Analysis
Antigen Clone Dilution Source
CD3 Polyclonal 1:100 Dako
CD4 1F6 1:40 Novocastra
CD8 C8/144B 1:50 Dako
CD2 AB75 1:160 Novocastra
CD5 4C7 1:100 Novocastra
CD7 CD7-272 1:50 Novocastra
bF1 8A3 1:20 Endogen
TCRg g3.20 1:100 Thermo Scientiﬁc
CD30 1G12 1:50 Novocastra
ALK1 ALK1 1:400 Dako
TIA1 2G9A10FS 1:1000 Immunotech
Granzyme-B GrB-7+D170 1:100 Monosan
Perforin KM585 PI-8 1:10 Vector
CD56 1B6 1:50 Novocastra
LMP1 CS1-4 1:400 Dako
Ki-67 MIB-1 1:50 Abcam
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(PCNSTL) varies from 3.6% (France), 8.5% (Japan) to 2%
(8 cases out of 370 patients) in the largest PCNSL series from
the western world.9 Choi et al10 described a somewhat higher
percentage of T-cell lymphomas (16.7%, 7/42 cases) in their
series of PCNSL from Korea.
The most recently published large case series from the
International Primary CNS Lymphoma Collaborative
Group described 45 patients with PCNSTL.1 In this series,
20 patients (44%) had Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1. Twenty-six
patients (58%) had involvement of cerebral hemispheres,
and 16 (36%) had lesions of deeper brain sites. The median
disease-speciﬁc survival was 25 months, and multivariate
analyses demonstrated an association of better ECOG per-
formance status and methotrexate use with longer survival.
However, a detailed morphologic and immunophenotypic
analysis is not available. In a separate study of PCNSL other
than DLBCL, outcomes for 7 patients with peripheral T-cell
lymphomas (PTCL) were described; these T-cell lymphomas
demonstrated similar or favorable clinical outcomes as
TABLE 2. Clinical Features, Imaging, Treatment, and Outcome of PCNSTLs
Final
No. Age Sex Clinical Presentation Imaging Treatment Outcome
1 21 M Headache Solitary, right occipital mass
(2 cm)
Steroids, Thiotepa+HD
MTX+XRT
NA
2 61 M NA Solitary frontal mass NA DOD
3 81 M NA Solitary, right occipital mass
(2 cm)
Steroids AwoD (64mo)
4 54 M Transient right facial and
upper limb sensory
symptoms, headaches, facial
asymmetry, and speech
diﬃculties
Solitary, left frontal mass HD MTX+XRT AwD (47mo)
5 60 M Headache Solitary, left cerebellar mass
(2.2 cm)
Chemotherapy DOD (3mo)
6 57 M Diﬃculties short-term
memory, ataxia, right leg
weakness
Multiple lesions throughout
the brain, largest left
parietal lobe (3.5 cm)
NA NA
7 69 M NA Solitary, right parietal mass MTX+AraC+Leuco-
vorin+Procarbazine
hydrochloride
AwD
8 81 M Altered mental status Right occipital and temporal
mass
2MTX+bendamustine AwD (4mo)
9 63 F Left-sided weakness Periventricular and
striatocapsular
abnormalities
No treatment DOD
10 42 F Seizures Right frontal and temporal
masses
Dexamethasone+HD
AraC+3MTX
+17XRT
AwD (5mo)
11 21 F Pregnant, headaches,
behavior changes
Solitary parietal mass
(775 cm)
NA NA
12 67 F Aphasia and facial paralysis Multiple bilateral frontal and
occipital masses
6HD MTX+XRT AwoD (56mo)
13 31 M Seizure and slow (2 y) decline
in mental function, weight
loss, confusion
Bilateral temporal lobes
enhancement
NA NA
14 56 F Headache Solitary right frontal mass NA NA
15 57 M Progressive neurological
decline
Multiple lesions in the basal
ganglia, midbrain,
brachium pontis and
cerebellar hemispheres
NA DOD
16 43 M Fever, nausea, vomiting
(1mo)
Multiple meningeal lesions
(dural, leptomeningeal,
spinal, superﬁcial cortical
parietal, right cerebellum,
and medulla involvement)
NA DOD
17 61 F Weakness of right superior
extremity, paresthesia, mild
paralysis
Diﬀuse enhancement Dexamethasone DOD (1mo)
18 62 F History of multiple sclerosis,
left lower extremity weakness
(3mo)
Solitary right frontal mass NA NA
AwD indicates alive with disease; AwoD, alive without disease; DOD, died of disease; HD, high dose; IT, intrathecal; MTX, methotrexate; NA, not available; XRT,
radiation.
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compared with previously reported data on DLBCLs.7 Al-
though several case series (referenced above) have made
valuable contributions to the understanding of the clinical
characteristics of PCNSTL, an extensive pathologic analysis/
description is lacking. Several case reports and smaller case
series have described the pathology and immunophenotype
in varying detail.11–26
The goal of this study was to describe in a com-
prehensive manner not only the clinical characteristics but
also the histologic, immunophenotypic, and molecular
characteristics of 18 PCNSTLs identiﬁed from the con-
sultation ﬁles of the hematopathology division of the
authors’ institution.
MATERIALS AND METHODS
Case Selection
Nineteen cases of PCNSTLs were identiﬁed from
the pathology database of the Hematopathology Section,
Laboratory of Pathology, National Cancer Institute, be-
tween 2000 and 2014. Eighteen cases were submitted in
consultation as brain biopsies. One additional autopsy
case was contributed by 1 of the coauthors (D.C.M.).
None of the patients had lymphadenopathy or evidence
of extra-CNS disease at the time of CNS presentation.
One patient had a soft tissue mass involved by PTCL 3
months after diagnosis of the CNS lesion; given the close
proximity of these lesions, this case was excluded. This
study was approved by the Institutional Review Board of
the National Cancer Institute.
Immunohistochemistry Studies
Immunohistochemical studies were performed on
available formalin-ﬁxed paraﬃn-embedded tissue (FFPE)
sections using the following antibodies: CD2, CD3, CD4,
CD5, CD7, CD8, CD30, CD56, bF1, TCRg, TIA1,
granzyme-B, perforin, LMP1, MIB-1, and ALK1. The
panel of antibodies, clone, dilution, and source are listed
in Table 1. A case was scored as positive if >50% of the
atypical lymphoid cells expressed the antigen. MIB-1 was
scored as low (<33%), moderate (33% to 66%), and
high (67% to 100%) on the basis of the percent of lym-
phoid cells positive.
TABLE 3. Morphology, Immunophenotype, TCR Clonality, and Mutation Analysis
Case
No. Diagnosis Size Cells Necrosis
Perivascular
Cuﬃng
Meningeal
Spread CD2 CD3 CD4 CD8 CD5
1 PTCL, NOS Small-medium Pos Pos Neg NA Pos Pos Neg Pos
2 PTCL, NOS Medium Pos Pos Pos Pos Pos Neg Pos Pos F
3 PTCL, NOS Small Neg Neg Neg Pos Pos Pos Neg Pos
4 PTCL, NOS Small-medium Pos F Pos Neg Pos
F
Pos Neg Pos Pos
5 PTCL, NOS Medium Pos Neg Neg Pos Pos Mix Mix Pos F
6 PTCL, NOS Large Neg Neg Neg Pos Pos Pos Neg Pos F
7 PTCL, NOS Medium-large Pos Pos Neg Pos Pos Pos Neg Pos
8 PTCL, NOS Medium-large Pos Pos Neg Pos Pos Pos Neg Pos
9 PTCL, NOS Small-medium Neg Neg Neg Neg Pos Neg Pos Neg
10 PTCL, NOS Small-medium Pos Pos Pos Pos Pos Neg Pos Pos F
11 PTCL, NOS Medium-large Pos Pos Pos Pos Pos Neg Pos Pos F
12 PTCL, NOS Small Pos Pos Pos NA Pos Neg Pos Pos F
13 PTCL, NOS gd Small-medium Neg Pos Neg Pos
F
Pos Neg Pos Pos
14 PTCL, NOS gd Small-medium Neg Pos Neg NA Pos Neg Pos Neg
15 PTCL, NOS TCR
silent
Medium Neg Neg Neg Pos Pos Neg Pos Neg
16 ALCL, ALK pos Medium-large; “Hallmark”
cells
Pos Pos Pos Neg Neg Neg Neg Neg
17 ALCL, ALK neg Large, “hallmark” cells Neg Neg Neg Pos Pos Neg Pos
W
Pos
18 ALCL, ALK neg Large, “hallmark” cells Pos Neg Neg NA Pos
W
NA NA Neg
F indicates focal; GrB, granzyme-B; LMP1, EBV latent membrane protein; mix, mixed, both CD4-positive and CD8-positive cells present; mod, moderate; equiv,
equivocal; NA, not available; neg, negative; no amp, no ampliﬁcation products; not interp, not interpretable; pos, positive; rest, restricted; susp, suspicious; TRG, T-cell
receptor gene rearrangement; US, unsatisfactory; w, weak; bF1, T-cell receptor bF1.
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In Situ Hybridization for Epstein Barr Virus–
encoded RNA
In situ hybridization was performed on FFPE tis-
sue, using EBER1 DNP probe supplied by Ventana on an
automated stainer (Ventana-Benchmark XT, Tucson,
AZ). The ISH iView blue plus system with alkaline
phosphatase and nitroblue tetrozolium and 5-bromo-4-
chloro-3-indolyl phosphate substrate with Fast Red
contrast was used for visualization, with relevant con-
trols.
Molecular Studies
For TRG rearrangement, DNA was extracted from
FFPE tissue blocks and either (1) single multiplexed
polymerase chain reaction was carried out with primers
directed against all known Vg family members, and the
Jg1/2, JP1/2, and JP joining segments27 or (2) 3 separate
reactions were performed, 1 with primers Vg101, Vg11,
and Jg12 (set 1), a second with primers Vg101, Vg11, and
Jp12 (set 2), and a third with primers Vg9 and Jg12 (set 3),
the ﬁrst 2 performed according to the method of Slack
et al28 and the third according to a validated in-house
method. Products were analyzed either by acrylamide gel
electrophoresis or by capillary electrophoresis on an ABI
3130xl Genetic Analyzer (Applied Biosystems, Foster
City, CA). The results were interpreted as polyclonal,
restricted, or clonal. The “restricted” TRGg category was
deﬁned as an abnormal rearrangement pattern with small
peaks that did not meet criteria for monoclonality, as
previously described.29
Mutational Analysis
DNA samples were analyzed for somatic mutations
within genes previously implicated in the pathogenesis of
mature T-cell lymphomas using a targeted next-gen-
eration sequencing (NGS) strategy.30 The mutation panel
includes targeted regions of 38 genes previously reported
to be mutated in T-cell lymphomas as well as targeted
regions of genes involved in T-cell signaling focused on
the JAK/STAT signaling pathway. The amplicon libraries
were generated with 2 custom primer pools (total 227
amplicons) and were sequenced on an Ion Torrent Per-
sonal Genome Machine (PGM) (Life Technologies). The
paraﬃn-embedded tissue sections were macrodissected to
enrich for tumor cells with at least 20% tumor content.
DNA was extracted using the Qiagen QIAamp DNA
FFPE Tissue Kit and performed on a QIAcube according
to the instructions of the manufacturer. Further details
regarding the NGS methods (SDC1) and a list of the
genes analyzed (SDC2) are included in Supplemental
TABLE 3. Morphology, Immunophenotype, TCR Clonality, and Mutation Analysis
Case
No. CD7 CD56 BF1 TCRc TIA1 GrB Perf CD30 ALK1 EBV Ki-67 TRG PCR Mutations
1 NA Equiv NA NA NA NA NA NA NA Neg (LMP1) NA Pos NA
2 Neg Neg Pos NA Pos Pos NA Neg NA Neg (LMP1) NA Pos NA
3 Pos F Neg Pos NA Pos Neg Neg Neg NA Neg Mod Susp DNMT3A,
c.2207 G>T,
p.Arg736Leu
4 Pos Neg Pos NA Pos Neg NA Neg Neg Neg High Pos WT
5 Pos F Neg Pos NA Pos Neg Neg Neg Neg Rare Mod Rest WT
6 Pos F Not interp Pos NA Neg Neg Neg Neg Neg Neg High No amp NA
7 Pos F Neg Pos Neg Pos Pos Pos F Neg Neg Neg Mod Pos WT
8 Pos F Neg NA NA NA NA NA Neg NA Neg Mod Pos NA
9 Pos Neg Pos Neg Pos Pos Pos Neg NA NA High Pos KRAS, c.34 G>A,
p.Gly12Ser;
STAT5B,
c.1924 A>C,
p.Asn642His;
JAK3, c.1533 G>T,
p.Met511Ile
10 Pos Neg Pos Neg Pos Pos Pos Neg Neg Neg High Pos WT
11 NA NA Pos Neg Pos Pos NA Neg Neg Neg NA Pos WT
12 NA Neg Neg NA Pos NA NA NA NA Rare High Pos NA
13 Pos NA Neg Pos Pos Pos NA Neg NA Neg Mod Pos WT
14 NA NA Neg Pos NA NA NA NA NA NA Mod Pos TET2, c.4034 A>C,
p.Tyr1345Ser
15 Pos Neg Neg Neg Pos Pos NA Neg NA Neg High Pos GNB1,c.232 A>G,
p.Lys78Glu;
STAT3,
c.1981G>C,
p.Asp661His
16 Neg Neg US NA Pos Pos Pos Pos Pos C Neg High Pos WT
17 Pos F Not interp Pos Neg Pos F Pos NA Pos Neg NA Mod No amp NA
18 NA Neg NA NA Neg NA NA Pos Neg Neg High Pos NA
F indicates focal; GrB, granzyme-B; LMP1, EBV latent membrane protein; mix, mixed, both CD4-positive and CD8-positive cells present; mod, moderate; equiv,
equivocal; NA, not available; neg, negative; no amp, no ampliﬁcation products; not interp, not interpretable; pos, positive; rest, restricted; susp, suspicious; TRG, T-cell
receptor gene rearrangement; US, unsatisfactory; w, weak; bF1, T-cell receptor bF1.
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Digital Content ﬁles (Supplemental Digital Content 1,
http://links.lww.com/PAS/A305).
RESULTS
Clinical Features
Eighteen conﬁrmed cases of PCNSTL were identi-
ﬁed. The clinical features of these cases are summarized
in Table 2. There were 11 men and 7 women, with a
median age of 58.5 years (range, 21 to 81 y). The
clinical manifestations of patients ranged from headache,
aphasia, facial paralysis, facial and upper limb sensory
abnormalities, speech abnormalities, ataxia, leg weakness,
diﬃculties in short-term memory, etc. Imaging studies
showed that 15 patients had supratentorial lesions, and 3
had cerebellar involvement. Solitary tumor was seen in 9
cases, multiple masses in 8, and 1 showed diﬀuse en-
hancement of meninges. None of the patients presented
with or developed lymphadenopathy at any time point.
One case of anaplastic large cell lymphoma (ALCL),
ALK-positive diagnosed at autopsy (case 16), had ex-
tensive dural, leptomeningeal, and spinal disease. At au-
topsy one out of several lymph nodes tested showed rare
scattered CD30-positive and ALK-positive cells, which
were interpreted as secondary lymph node involvement by
virtue of the high burden of the disease in the CNS and
FIGURE 1. ALCL, ALK-positive (case 16). A, Multiple tan-white lesions are attached to the left side of falx dura. B, The lep-
tomeninges are extensively involved. C, The cells are medium to large with irregular nuclei; occasional larger cells have eccentric
kidney or horse shoe–shaped nuclei and abundant cytoplasm consistent with “hallmark cells.” D, Parenchymal involvement was
also seen along with perivascular infiltrates (E) as well as extensive spinal and nerve root involvement (F). The cells are positive for
CD30 (G), ALK, nuclear, and cytoplasmic (H), focal EMA (I), CD43 (J), TIA1 (K), and granzyme B (L).
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the lack of lymphadenopathy or histologically conﬁrmed
disease elsewhere.
Treatment information was available for 10 pa-
tients: 4 received chemotherapy and radiotherapy, 3 were
treated with chemotherapy alone, 2 received only
steroids, and 1 patient did not receive treatment due to
a poor performance status. The outcome data were
available for 12 patients. With a median follow-up of 5
months (range, 1 to 64mo), 2 patients are alive without
disease, 4 patients are alive with disease, and 6 patients
died of disease.
Morphologic Findings
The PCNSTLs were classiﬁed as PTCL, not other-
wise speciﬁed (NOS) (15 cases), ALCL, ALK-negative (2
cases), and ALCL, ALK-positive (1 case). The salient
morphologic ﬁndings are summarized in Table 3. Al-
though most cases were submitted as small biopsies, de-
tailed gross examination was available for 1 ALCL,
ALK-positive diagnosed at autopsy (case 16). This case
demonstrated tan-white nodules on the dural surface
(mostly left-sided) with size ranging from 0.3 to 0.8 cm
(Fig. 1A). Leptomeningeal involvement was observed
grossly in the lower thoracic and lumbar spinal cord with
extension to the nerve roots of cauda equina. Overall, 5
cases had demonstrable leptomeningeal involvement.
Microscopically, most PTCL, NOS cases (11/15)
were composed of atypical small and/or medium-sized
lymphocytes with dense, hyperchromatic nuclei, irregular
nuclear outlines, occasional distinct nucleoli, and scant
cytoplasm (Fig. 2). Medium to large cells (3 cases) or
mostly large cells (1 case) were predominant in the re-
mainder (Fig. 3). Three cases showed features character-
istic of ALCL, being composed of large cells with
vesicular chromatin, evident nucleoli, and abundant cy-
toplasm; frequent “hallmark” cells were identiﬁed
(Fig. 1C). The tumor cells formed cohesive aggregates/
sheets in 2 cases and were scattered throughout the white
matter in 1 case.
Prominent perivascular inﬁltration was evident in
most cases (11/18) (Fig. 4), with tumor cells expanding the
FIGURE 2. PTCL, NOS (case 1). A, Expansion of the Virchow-Robin space by an atypical lymphoid infiltrate. B, Broad areas of
necrosis are visible. C, Neoplastic cells are small to medium in size with irregular nuclei; abundant admixed histiocytes are visible.
D, The atypical cells are positive for CD3.
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Virchow-Robin space. Areas of necrosis were visible in 11
cases. Several cases demonstrated signiﬁcant background
gliosis and abundant histiocytes probably related to ne-
crosis.
Immunophenotype
The atypical lymphoid cells expressed CD3 in all
cases except 1 (ALCL, ALK-positive) (Table 3). Ten of 17
were CD8-positive, and 5/17 were CD4-positive, with no
case showing dual expression. Partial or total loss of T-
cell antigens was seen in 4/15 cases for CD2, 11/18 cases
for CD5, and 8/13 cases for CD7. No case expressed
CD56, although high background staining for CD56 (as
expected in CNS tissues) made interpretation diﬃcult.
Ten of 14 cases showed bF1 immunostaining. Among the
4 bF1-negative cases, a gd T-cell derivation was conﬁrmed
in 2 by positivity for TCRg (Fig. 5), 1 case was TCR
silent, and 1 lacked material for TCRg. Regardless of
histologic type, most of the cases showed a cytotoxic
phenotype with expression of TIA1 in 13/15, granzyme-B
in 9/13, and perforin in 4/7. Three (of 15) cases showed
strong, uniform expression of CD30, corresponding to
the diagnosis of ALCL, with one of these being positive
for ALK, with both nuclear and cytoplasmic immunor-
eactivity. All 16 cases analyzed showed a brisk pro-
liferation index as per Ki-67, with at least 50% of
lymphoid cells positive. Rare Epstein Barr virus–positive
cells were present in 2/15 cases studied by Epstein Barr
virus–encoded RNA and/or LMP1. Stains for BCL6,
CD10, and PD-1 (CD279) were performed on a single
CD4-positive case (case 5) and were negative.
T-cell Receptor Gene Rearrangement and
Mutational Analysis
The quality of DNA allowed for further analysis in
16/18 cases, with 2 cases showing no ampliﬁcation
products. A clonal rearrangement pattern was identiﬁed
in 14 cases; 1 case showed a restricted pattern, and 1 was
considered suspicious for a signiﬁcant clonal rearrange-
ment.
Eleven of 18 cases (1 of which was ALCL, ALK-
positive) were analyzed with a custom NGS mutation
panel targeting mutation hotspots in genes previously
reported to be mutated in T-cell lymphomas and in genes
involved in T-cell signaling pathways. Four cases of
PTCL, NOS were found to have somatic mutations (4/11,
36%); 2 had >1 mutation, and none showed overlapping
mutations. Case 3 displayed a DNMT3A (c.2207G>T;
p.Arg736Leu) mutation. Case 9 was found to have KRAS
(c.34G>A; p.Gly12Ser), STAT5B (c.1924A>C,
p.Asn642His), and JAK3 (c.1533G>T; p.Met511Ile)
mutations. Case 14, PTCL, NOS of gd T-cell derivation
showed a TET2 (c.4034A>C; p.Tyr1345Ser) mutation,
and case 15, silent for TCR expression by immunostains,
contained both GNB1 (c.232A>G; p.Lys78Glu) and
STAT3 (c.1981G>C; p.Asp661His) mutations. All re-
maining cases were wild type at the targeted sites in the 38
genes included in the panel.
DISCUSSION
Through this study, we describe in detail the histo-
pathologic, immunophenotypic, and molecular charac-
teristics of 18 cases of PCNSTLs. Diagnosis of these
FIGURE 3. PTCL, NOS (case 6). A, A minority of cases, such as
this one, contained large atypical cells with irregular nuclear
contours, vesicular nuclei, and basophilic nucleoli. The neo-
plastic cells are CD3-positive (B) and CD4-positive (C).
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lesions is often a challenge, with the main diﬀerential
being an inﬂammatory process, as the neoplastic T cells
were small to medium in size in the majority of cases,
most of which were classiﬁed as PTCL, NOS. The diag-
nosis was more readily made in 3 cases of ALCL, 1 of
which was positive for ALK. A helpful feature was
prominent perivascular inﬁltration; perivascular cuﬃng is
a common feature among both primary CNS B-cell and
T-cell lymphomas. In addition, necrosis, gliosis, and his-
tiocytic inﬁltration were seen in a signiﬁcant number of
cases. In contrast, abundant plasma cells, neutrophils, or
eosinophils were absent; when present, these would favor
an inﬂammatory process.
Given the small cell size in many cases, im-
munohistochemical studies and molecular analysis were
key in diagnosis. The most common antigenic aberrancies
included complete or partial loss of CD5 (61%) and CD7
(62%). Loss of CD3 was very uncommon, restricted to 1
case of ALCL. More than half were CD8-positive. Al-
though most cases appeared to be derived from ab T cells,
4 cases were bF1 negative, suggesting a gd T-cell deriva-
tion. However, only 2 were positive for TCRg by im-
munohistochemistry; 1 case was noted to be TCR silent,
also a major aberrancy.31 The majority of cases had a
cytotoxic phenotype, irrespective of the histologic sub-
type, as determined by staining with granzyme-B, per-
forin, and TIA1. Prior studies have shown a high
incidence of a cytotoxic phenotype in extranodal as op-
posed to nodal T-cell lymphomas.32
Molecular testing for TRG rearrangement played an
important role in the diagnosis of PCNSTL. A clonal
process was conﬁrmed in 14/16 cases with adequate
DNA, whereas 2 others were either suspicious or showed
a restricted pattern. PCNSTLs have not been studied
previously for molecular aberrations. Four of 11 PTCLs,
NOS studied (36%) had mutations involving STAT3,
STAT5B, JAK3, DNMT3A, KRAS, TET2, and GNB1
genes. Interestingly, no mutation was common to multi-
ple cases, suggesting molecular heterogeneity. However,
the ﬁndings in 2 cases with mutations in STAT5B,
STAT3, and JAK3 support the importance of the JAK/
STAT pathway in T-cell malignancies. Activating muta-
tions of STAT3, STAT5B, and JAKs have been reported
with high frequency in large granular lymphocytic leuke-
mia,33,34 gd hepatosplenic T-cell lymphomas,30 T-prolym-
phocytic leukemia,35 nonhepatosplenic gd T-cell
lymphomas,36 and natural killer/T-cell lymphoma.37 Other
studies have demonstrated the importance of the JAK/
STAT pathway in both ALK-positive and ALK-negative
ALCL.38,39 Thus, our data suggest that JAK and/or STAT
inhibitors might represent potential treatment options in
patients with PCNSTLs.
DNMT3A and TET2 mutations have been recently
reported as important events in the pathobiology of
mainly nodal lymphomas of TFH derivation.
40,41 Inter-
estingly, we found evidence of these mutations in
PCNSTLs; 1 case with a mutation in DNMT3A had a
CD4-positive phenotype, whereas a second case with a
TET2mutation was of gd T-cell derivation. TET2 has not
previously been implicated in the pathogenesis of gd T-
cell lymphomas.
Clinically, most of our cases of PCNSTL had supra-
tentorial disease and at presentation had solitary masses.
Most patients received some form of chemotherapy com-
bined with steroids with or without intrathecal methotrexate
and/or brain irradiation. Six patients had expired at the time
of this study. In the largest series of PCNSTL of the western
world (International Primary CNS Lymphoma Collabo-
FIGURE 4. PTCL, NOS (case 8). A, Marked perivascular infiltration is present. B, The infiltrate is composed of small to medium
atypical lymphocytes with significant background gliosis and abundant histiocytes. The atypical cells are strongly positive for CD2
(C), more variably positive for CD5 (D), positive for CD4 (E), and negative for CD8 (F).
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FIGURE 5. Phenotypic aberrancies in PCNSTL. A–D, PTCL, NOS with TCR silent phenotype (case 15). A, Monomorphic medium-
sized atypical lymphocytes with irregular nuclear contours, vesicular chromatin, and occasional nucleoli. The neoplastic T cells are
CD8-positive (B), TIA1-positive (C), and bF1-negative (D). TCRg was also negative (not shown). E–H, TCRg-positive cases (cases 13
and 14). The cells are mostly small to medium with irregular nuclear contours, admixed occasional larger cells, and demonstrate
prominent perivascular cuffing (E and G). The cells are strongly positive for TCRg immunostain (F and H).
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rative Group),1 the clinical characteristics were similar to
those of PCNSLs in general6,9,42 including the median age
(approximately 60y), propensity for supratentorial involve-
ment, and male predominance. Similarly, PCNSLs of both
B-cell and T-cell types are clinically aggressive, with median
survivals of <2 years.1,6,9,42
Interestingly, a diﬀerence in prognosis based on
morphology (ie, small, medium, vs. large cells) was not
present for PCNSTL.1 In a more recent study by Lim
et al,7 9 patients with primary CNS PTCL were identiﬁed
and demonstrated relatively favorable clinical outcomes
as compared with primary CNS DLBCL. However, other
than CD3 positivity in these cases, further histologic,
immunophenotypic, and molecular data were not speci-
ﬁed. Interestingly, a Korean study revealed a much higher
percentage of PCNSTL cases (16.7%) of all PCNSLs,10
signiﬁcantly higher than that reported in western studies.
In a study by Levin et al,16 5 patients out of a cohort
of 100 patients with PCNSL had T-cell lymphoma, and
all of them presented with isolated leptomeningeal in-
volvement. However, in the study describing the largest
PCNSTL cohort, only 1 of 45 patients had lep-
tomeningeal involvement.1 In the other cases described in
their study, the parenchyma of the cerebral hemispheres
(cortex and white matter) were the most frequent site
(64%) followed by deep brain structures. This is similar to
the known manifestations of B-cell PCNSL.
In our study leptomeningeal involvement was
present in 5 cases and was extensive in 1 (case 16, ALCL,
ALK-positive). Involvement of the leptomeninges in
ALCL is a common feature. Of the 24 cases of primary
CNS ALCL that have been described,21,25,43–61 10 cases
demonstrated some degree of dural or leptomeningeal
involvement. In addition, there are 2 documented cases of
primary dural ALCL without CNS parenchymal in-
volvement.44,45 In 1 case of ALCL from our series, the
bulk of the disease was in the leptomeninges, and the
clinical syndrome was dominated by meningitic signs and
symptoms. Of the reported ALCL cases, 13 were ALK-
positive, and 10 were ALK-negative, whereas data on 3
cases were unavailable. As expected, ALK positivity
seems to correlate with a younger age and better prog-
nosis (similar to that observed in systemic ALCL). In-
terestingly, leptomeningeal involvement does not seem to
confer a worse prognosis.40 Secondary involvement of the
CNS is very rare in most PTCLs, being most often re-
ported in ALCL in approximately 1% of cases.62 The
only PTCL that frequently involves the CNS is adult T-
cell leukemia/lymphoma, which is a systemic disease in
most patients.63
In conclusion, the diagnosis of T-cell lymphomas in
the CNS is challenging, especially considering that the
vast majority of these lymphomas have small or inter-
mediate-sized cells with variable cytologic atypia. These
need to be diﬀerentiated from reactive T-cell inﬁltrates
and encephalitis caused by infections and autoimmune
diseases. A combination of morphologic assessment, im-
munophenotypic aberrancies, and demonstration of clo-
nal T-cell receptor rearrangement helps in establishing the
diagnosis of a T-cell lymphoma. Preliminary genetic
analysis identiﬁed mutations in genes involved in other
mature T-cell malignancies but no common recurrent
genetic events.
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